Trial Profile
A Multicenter, Retrospective study to evaluate Brigatinib in patients with ALK-Positive Alectinib-Refractory advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2018
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jul 2018 New trial record
- 20 Jun 2018 Results published in the Journal of Thoracic Oncology